8 November 2019
The major issues of introducing medical combination inventions to the market
A transdermal patch is a galenic form incorporating a source of active ingredient that is released slowly while attached to the skin. Its aim is for the drug to enter the systemic flow through the skin surface and not the pharmaceutical’s action in the skin itself.
As we keep getting older and older, steadily we add more pharmaceuticals in our daily lives, and for this motive, the patches that attach to the skin get a fundamental role to ward off problems due to a high consumption of drugs, especially in the elderly age, and also for your comfort.
Medicine-device combination inventions, such as transdermal patch, introduced a new dynamic on medical product evolution, regulatory ratification, and corporate cooperation that provide priceless lessons for the development of new kinds of combination products. Research show that the biggest barrier to launch a new sort of combination products is the determination of the supervisory center that would be to oversee its authorization, and so the device contract. The first product of a recent kind of combination product gives a learning chance for the regulator and the benefactor. As soon as the first invention is approved, the leading regulatory center is determined, and the confusion about the entire kind of combination solutions is drastically diminished.
The sponsor developing a new type of combination products undertakes a central role in diminishing this doubt by advising the decision on the most important purpose of the combination product. This resolution influences the character of the firms that will lead the implementation of these products into the market.